Small Molecule Therapeutics Targeting Amyloid-β in Alzheimer's Disease: Mechanisms, Clinical Progress, and Future Strategies.

Exploratory analyses also suggested a possible cognitive benefit in APOE4 carriers based on Trail Making Test-B results, but this did not reach statistical significance [ 61 ].

also in 111,027 other papers

In phase 2 trials, no benefit overall was observed in cognition, although exploratory analyses showed a trend toward improvement in patients with low CSF p-tau217, defined by the median cutoff.

also in 53,322 other papers

In post-hoc analyses, participants treated with Device 1 showed nominally significant improvements in cognition, including ADAS-Cog12 and Activities of Daily Living for Mild Cognitive Impairment (ADL-MCI), accompanied by increases in CSF Aβ42/40 and Aβ42/total tau ratios [ 139 ].

also in 7,732 other papers